Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 377.00
Bid: 374.00
Ask: 376.50
Change: -5.50 (-1.44%)
Spread: 2.50 (0.668%)
Open: 381.00
High: 384.00
Low: 373.50
Prev. Close: 382.50
CHG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Funding Awards

18 Mar 2024 07:00

RNS Number : 1412H
Chemring Group PLC
18 March 2024
 

FOR IMMEDIATE RELEASE 18 MARCH 2024

 

CHEMRING GROUP PLC ("Chemring", the "Group" or the "Company")

 

c.£90m FUNDING AWARDS

 

Chemring notes the announcement made by the European Commission regarding its allocation of funding in support of boosting defence production within Europe, and we welcome its public announcement of awards totaling ?66.7m (£57m) made to our Norwegian subsidiary, Chemring Nobel.

 

These awards, which are part of the Act in Support of Ammunition Production ("ASAP") programme, are a direct response to the European Council's call in March 2023 to urgently deliver ammunition, and missiles if requested, to Ukraine and to help Member States refill their stocks by introducing targeted measures. This Regulation aims to strengthen the responsiveness and ability of the European Union's defence industry to ensure the timely supply of ammunition and missiles in Europe, and includes measures to support production capacities and tackle identified bottlenecks throughout the industrial supply chain.

 

Further information can be found on the European Commission website: https://defence-industry-space.ec.europa.eu/eu-defence-industry/asap-boosting-defence-production_en

 

Chemring is also pleased to report that it has received further grant funding of 428 million NOK (£32m) from the Government of Norway. This co-financing will boost capacity and production at Chemring Nobel and will significantly strengthen Norwegian production capacity for critical defense products.

 

Further information can be found on the Norwegian government website: https://www.regjeringen.no/no/aktuelt/milliardstotte-til-norsk-forsvarsindustri/id3029866/.

 

Grant agreements are expected to be signed over the coming months.

 

Both grants support Chemring's decision to invest in doubling the capacity of this facility over the medium-term, and reinforces Chemring Nobel's position as a key strategic supplier to NATO.

 

 

For further information:

Rupert Pittman Group Director of Corporate Affairs, 01794 463401

Chemring Group PLC

 

James McFarlane MHP Communications 020 3128 8100

Ollie Hoare

Cautionary statement

 

This announcement contains forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as anticipate, target, expect, estimate, intend, plan, goal, believe, will, may, should, would, could, is confident, or other words of similar meaning. Undue reliance should not be placed on any such statements because they speak only as at the date of this document and, by their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results, and Chemring's plans and objectives, to differ materially from those expressed or implied in the forward-looking statements. There are a number of factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are: increased competition, the loss of or damage to one or more key customer relationships, changes to customer ordering patterns, delays in obtaining customer approvals for engineering or price level changes, the failure of one or more key suppliers, the outcome of business or industry restructuring, the outcome of any litigation, changes in economic conditions, currency fluctuations, changes in interest and tax rates, changes in raw material or energy market prices, changes in laws, regulations or regulatory policies, developments in legal or public policy doctrines, technological developments, the failure to retain key management, or the key timing and success of future acquisition opportunities or major investment projects. Chemring undertakes no obligation to revise or update any forward-looking statement contained within this announcement, regardless of whether those statements are affected as a result of new information, future events or otherwise, save as required by law and regulations.

 

Notes to editors

 

· Chemring is a FTSE250 global business that specialises in the manufacture of high technology products and the provision of services to the aerospace, defence and security markets

· Employing approximately 2,600 people worldwide, and with production facilities in four countries, Chemring meets the needs of customers in more than fifty countries

· Chemring is organised under two strategic product segments: Sensors & Information and Countermeasures & Energetics

· Chemring has a diverse portfolio of products that deliver high reliability solutions to protect people, platforms, missions and information against constantly changing threats

· Operating in niche markets and with strong investment in research and development ("R&D"), Chemring has the agility to rapidly react to urgent customer needs

 

www.chemring.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRQKOBPPBKDPND
Date   Source Headline
30th Apr 201411:34 amRNSDirector/PDMR Shareholding
29th Apr 20141:20 pmRNSDirector/PDMR Shareholding
29th Apr 201412:42 pmRNSPDMR Shareholding
29th Apr 201411:59 amRNSDirector/PDMR Shareholding
29th Apr 201411:58 amRNSDirector/PDMR Shareholding
29th Apr 201411:57 amRNSDirector/PDMR Shareholding
29th Apr 201411:14 amRNSHolding(s) in Company
24th Apr 20144:30 pmRNSPublication of Circular
24th Apr 20147:00 amRNSDisposal
15th Apr 201412:11 pmRNSDirector Declaration
14th Apr 201411:15 amRNSBlocklisting update
9th Apr 201410:12 amRNSAdditional Listing
26th Mar 20144:16 pmRNSDoc re. Ordinary & Special Resolutions
20th Mar 20142:04 pmRNSResult of AGM
3rd Mar 201410:11 amRNSTotal Voting Rights
27th Feb 20147:00 amRNSInterim Management Statement
6th Feb 201412:18 pmRNSHolding(s) in Company
3rd Feb 201410:43 amRNSTotal Voting Rights
3rd Feb 201410:37 amRNSHolding(s) in Company
31st Jan 20144:19 pmRNSHolding(s) in Company
30th Jan 20145:10 pmRNSHolding(s) in Company
29th Jan 20145:00 pmRNSHolding(s) in Company
27th Jan 20149:58 amRNSHolding(s) in Company
27th Jan 20147:00 amRNSDisposal
23rd Jan 20147:00 amRNSFinal Results
20th Jan 20142:45 pmRNSHolding(s) in Company
17th Jan 20144:45 pmRNSHolding(s) in Company
16th Jan 201410:14 amRNSHolding(s) in Company
10th Jan 201411:13 amRNSHolding(s) in Company
2nd Jan 20149:57 amRNSTotal Voting Rights
31st Dec 201310:58 amRNSHolding(s) in Company
23rd Dec 20131:57 pmRNSDirectorate Change
23rd Dec 20131:55 pmRNSDirectorate Change
18th Dec 201311:26 amRNSBlocklisting Interim Review
10th Dec 20138:31 amRNSHolding(s) in Company
26th Nov 20133:55 pmRNSHolding(s) in Company
25th Nov 20137:00 amRNSPOST-CLOSE STATEMENT
1st Nov 201310:36 amRNSTotal Voting Rights
18th Oct 20133:19 pmRNSHolding(s) in Company
14th Oct 20132:23 pmRNSHolding(s) in Company
11th Oct 20137:00 amRNSTrading Update
10th Oct 20131:13 pmRNSHolding(s) in Company
1st Oct 201310:06 amRNSTotal Voting Rights
24th Sep 201312:02 pmRNSHolding(s) in Company
17th Sep 20132:10 pmRNSHolding(s) in Company
2nd Sep 201310:11 amRNSTotal Voting Rights
28th Aug 201312:17 pmRNSHolding(s) in Company
28th Aug 20137:00 amRNSInterim Management Statement
19th Aug 20134:36 pmRNSAdditional Listing
31st Jul 20135:08 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.